Genmab (GMAB) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab A/S has announced the European Commission’s approval of TEPKINLY (epcoritamab) as a groundbreaking monotherapy for adults with relapsed or refractory follicular lymphoma, after two or more systemic therapies. This marks TEPKINLY as the first and only subcutaneous bispecific antibody authorized in the EU for this condition. The approval is supported by promising results from the EPCORE NHL-1 clinical trial showing high response rates in patients with limited treatment options.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.